Where Your Medicines and Vaccines Are Made: FDA Oversight of Foreign Factories and What Changed in 2025

A decade ago, a viral headline claimed that vaccines would be made in China without U.S. inspection, “all thanks to the Clinton Foundation.” The story mixed several real facts into a misleading claim. Vaccines sold in the United States must be licensed by the FDA, and the factories that make them are inspected. But the broader concern behind the headline, that much of America’s medicine supply depends on overseas factories that receive less scrutiny than U.S. plants, is real and has become a major policy issue.

This article explains where America’s medicines and vaccines are made, how the FDA oversees foreign factories, what problems inspections have uncovered, what changed in 2025, and what the issue means for patients.

Are most U.S. medicines really made in China? It is more complicated than viral claims suggest. The United States makes many of its own drugs, but it relies heavily on China and India for ingredients, especially the active ingredients and precursors in generic medicines. The FDA inspects foreign factories, though less often than domestic ones, and the concentrated supply chain has contributed to drug shortages and quality concerns.

Are U.S. Medicines Really All Made in China?

Not entirely. Viral claims overstate the case: the United States manufactures many finished drugs domestically, but it depends heavily on China and India for the active ingredients and chemical precursors, especially in generics. The claim centered on efforts by global health organizations, including the Clinton Health Access Initiative and others, to help manufacturers in developing countries produce affordable vaccines for low-income nations. In 2013, the World Health Organization prequalified a Japanese encephalitis vaccine made by a Chinese manufacturer, the first Chinese vaccine to meet WHO’s quality standards for purchase by United Nations agencies. WHO prequalification allows agencies such as UNICEF to buy vaccines for countries that rely on them; it does not authorize sale in the United States.

In the U.S., every vaccine must be approved by the FDA through a biologics license application, which requires clinical trial data and an inspection of the facility where the vaccine is made. Licensed vaccine manufacturers are subject to ongoing inspections. Most vaccines on the U.S. childhood and adult schedules are made by large manufacturers in the United States, Europe, and a few other countries. So the claim that Chinese vaccines would be sold to Americans without inspection was not accurate.

Where Are America’s Medicines Actually Made?

Drug production is global: finished medicines are made in the United States, Europe, India, and elsewhere, while many active pharmaceutical ingredients and their building blocks come from China and India. The picture for drugs is different. A medicine has two main parts: the active pharmaceutical ingredient (API), the chemical that produces the therapeutic effect, and the finished dosage form, such as a tablet or injection. Many brand-name drugs are made in the United States, Europe, and elsewhere, but generic drugs, which account for the large majority of U.S. prescriptions, rely heavily on manufacturers in India, and many APIs and their chemical building blocks come from China. India and China are the two countries with the most foreign drug facilities subject to FDA inspection.

This global supply chain has lowered prices but created vulnerabilities: drug shortages when a single overseas plant has problems, difficulty tracing where ingredients originate, and challenges ensuring consistent quality across thousands of facilities.

How Does the FDA Oversee Foreign Drug Factories?

The FDA inspects both domestic and foreign drug factories and can block imports from facilities that fail, but foreign plants are inspected less frequently, and the pandemic disrupted inspections. All facilities that make drugs for the U.S. market, domestic or foreign, must follow current good manufacturing practice regulations and are subject to FDA inspection. In practice, foreign oversight has differed in important ways. According to a legal analysis published on Mondaq, nearly 90 percent of FDA’s foreign inspections in fiscal year 2023 were preannounced, in contrast to the unannounced inspections typically conducted at U.S. facilities. The same analysis described an inspection backlog that included more than 340 plants in India and China, along with significant vacancies among FDA investigators, particularly in its China and India offices.

The Government Accountability Office has raised these concerns for years. As the FDA Law Blog noted, GAO reported in 2019 that the FDA’s practice of preannouncing foreign inspections up to 12 weeks in advance could give manufacturers the opportunity to fix problems before inspectors arrived, and repeated the concern in 2022 and 2024. Inspections in China fell sharply during the COVID-19 pandemic. Global Compliance News reported FDA drug and device inspection counts in China of 18 in fiscal 2021, 8 in 2022, 61 in 2023, 227 in 2024, and 81 in fiscal 2025 as of early May.

What Inspections and Investigations Have Found

Quality failures in foreign-made medical products have had serious consequences. In 2007 and 2008, heparin, a widely used blood thinner made with raw material sourced from China, was contaminated with a substance that mimicked heparin in standard tests. A 2008 investigation in the New England Journal of Medicine by David Blossom and colleagues identified 152 adverse reactions in 113 patients from 13 states and linked them to oversulfated chondroitin sulfate in the contaminated heparin.

In 2023, artificial tears made in India were linked to an outbreak of an extensively drug-resistant bacterium. A 2024 CDC report in Clinical Infectious Diseases by Grossman and colleagues identified 81 patients in 18 states; four of 54 patients with clinical cultures died within 30 days, and four of 18 patients with eye infections had an eye surgically removed. Other episodes, such as the discovery in 2018 of a probable carcinogen, a nitrosamine impurity, in blood pressure medicines containing valsartan from a Chinese manufacturer, led to large recalls.

FDA warning letters issued to foreign manufacturers in recent years have cited problems including data falsification, inadequate cleaning, failure to test incoming materials, and sterility assurance failures.

What Changed in 2025

On May 5, 2025, President Trump signed an executive order aimed at promoting domestic drug manufacturing that directed the FDA to increase inspections of foreign manufacturing plants, funded by higher fees on foreign facilities, and to strengthen enforcement of requirements for reporting the sources of active pharmaceutical ingredients. The next day, the FDA announced it would expand unannounced inspections at foreign facilities producing foods, essential medicines, and other medical products for U.S. consumers. As the law firm McGuireWoods noted, unannounced foreign inspections were not entirely new: in 2022, Congress directed the FDA to pilot such a program in India and China. The 2025 policy aimed to make them far more common.

Implementation faces practical challenges, including staffing. Pharma Manufacturing reported that a 2025 GAO report found 51 investigator vacancies at the FDA, many in roles critical to foreign inspections, and that GAO continued to consider foreign manufacturing oversight a high-risk area. Visa requirements, travel logistics, language barriers, and diplomatic considerations also complicate surprise inspections abroad.

Feature	U.S. facilities	Foreign facilities (historically)
Advance notice	Usually unannounced	Usually preannounced, sometimes weeks ahead
Inspection frequency	Risk-based, generally more frequent	Backlogs, especially after the pandemic
Staffing	Domestic investigators	Limited in-country staff; travel required
2025 policy direction	Continued unannounced inspections	Expanded unannounced inspections and higher fees

Why Does the Supply Chain Cause Drug Shortages?

When production of a key ingredient or drug is concentrated in a few overseas facilities, a single disruption, such as a factory shutdown or quality problem, can trigger widespread shortages. Quality problems at a single overseas factory can ripple through the U.S. health system. In 2023, the United States experienced severe shortages of the cancer drugs cisplatin and carboplatin after an FDA inspection found serious problems at a major manufacturing plant in India and the company halted production, forcing some hospitals to ration chemotherapy. Many sterile injectable generics, which are complex to make and earn low profits, depend on a small number of manufacturers, so a single plant’s shutdown can cause nationwide shortages. Experts point to low prices, limited manufacturing redundancy, and opaque supply chains as underlying causes, and many proposals to reduce shortages focus on diversifying production and rewarding reliable, high-quality manufacturers.

How Regulators Share the Work

The FDA cannot inspect every foreign facility as often as it might like, so it also relies on cooperation with other regulators. Under a mutual recognition agreement with the European Union, finalized in 2017 and fully implemented for human drugs in 2019, the FDA and EU regulators can rely on each other’s inspections of drug manufacturing facilities in their territories, freeing resources to focus on higher-risk regions. The FDA also participates in international cooperative programs and shares information with other regulators. However, no such agreement covers China or India, where the FDA must conduct its own inspections.

Small Molecules and Biologics

Traditional drugs are usually small molecules made through chemical synthesis, which can be done in many places with the right equipment and controls. Vaccines and other biologics, such as monoclonal antibodies, are made using living cells or organisms and require specialized facilities, tight process control, and extensive testing. Because biologic manufacturing is so complex, FDA licensure is closely tied to specific facilities and processes, and changes require regulatory review. This is one reason vaccine manufacturing for the U.S. market has remained concentrated among a relatively small number of established manufacturers with FDA-licensed facilities.

Are Generic Drugs as Safe and Effective as Brand Names?

Approved generic drugs must meet the same standards for quality, strength, and effectiveness as brand-name versions; occasional quality problems at specific factories do not mean generics in general are inferior. Generic drugs must contain the same active ingredient, strength, dosage form, and route of administration as the brand-name product and must demonstrate bioequivalence, meaning they deliver the active ingredient to the bloodstream at a similar rate and extent. The FDA reviews generic applications and the facilities that will manufacture them. Most generics perform as expected, and they have saved patients and health systems large sums. Concerns about quality typically relate to manufacturing lapses at particular facilities rather than to generics as a category.

What Patients Can Do

Ask your pharmacist. Pharmacists can tell you which manufacturer made your medication, and in some cases can source a different manufacturer’s version if you have concerns.

Watch for recalls. The FDA posts drug recalls and safety alerts, and pharmacies typically notify affected patients.

Report problems. If a medicine looks, smells, or works differently than expected, or causes an unexpected reaction, report it to your clinician and to the FDA’s MedWatch program.

Don’t stop medicines abruptly. Even during recalls, stopping some medicines suddenly can be dangerous; talk with your clinician or pharmacist first.

Be wary of online pharmacies. Buying medicines from unlicensed websites bypasses U.S. oversight entirely and increases the risk of counterfeit or substandard products.

The Bigger Picture

Most medicines Americans take, whether made in the U.S. or abroad, are safe and effective. Foreign manufacturing is not inherently unsafe; many plants in India, China, Europe, and elsewhere meet high standards. The concern is uneven oversight and concentrated supply chains, which can allow quality problems to go undetected and leave patients vulnerable to shortages. Policy proposals to address these issues include more and unannounced inspections, better supply chain transparency, incentives for domestic and diversified manufacturing, and international regulatory cooperation.

How to Read Your Medicine’s Label

Prescription labels from pharmacies usually list the drug name and strength, and many also identify the manufacturer, sometimes abbreviated. The package insert or the pharmacy’s printed information may name the company that holds the application, which is not always the company that physically makes the product, because many drugs are made under contract. The National Drug Code on the package identifies the labeler. Pharmacists can look up which company manufactured a specific lot. If you prefer a particular manufacturer, ask whether your pharmacy can stock it; availability depends on supply contracts and insurance.

Quality Signals and Recalls

Patients should contact a pharmacist if a refill looks different from previous fills without explanation, if tablets are discolored or crumbling, or if a medicine has an unusual odor. Changes in appearance often reflect a switch to a different manufacturer’s generic, which is normal, but pharmacists can confirm. FDA recalls are classified by risk, with Class I recalls involving the most serious potential health hazards. The FDA’s recall listings and drug shortage database are public, and many hospitals and pharmacies monitor them closely.

The Role of Price

Economists studying drug quality and shortages point to price pressure as a root cause. Generic drug prices in the United States are often very low, and purchasers frequently choose the cheapest supplier, giving manufacturers little reward for investing in higher quality or redundant production capacity. Some proposals would create quality ratings for manufacturers or pay more for reliable, high-quality supply, so that buyers can consider quality as well as price. Such reforms aim to make the market itself reward the kind of manufacturing that inspections try to enforce.

Efforts to Bring Manufacturing Home

Since the COVID-19 pandemic exposed supply chain vulnerabilities, U.S. policymakers have pursued efforts to expand domestic and allied manufacturing of essential medicines and their ingredients, including government contracts, tax incentives, and trade measures. Several pharmaceutical companies have announced new or expanded U.S. manufacturing investments. Building pharmaceutical plants takes years and substantial capital, and domestic production of low-cost generics may require sustained financial support to compete with overseas costs. Experts generally agree that diversification, rather than complete self-sufficiency, is the most realistic goal.

Common Misconceptions

“Chinese vaccines are being given to Americans without inspection.” Vaccines sold in the U.S. require FDA licensure, including facility inspections.

“All foreign-made drugs are unsafe.” Most meet FDA standards; the concern is uneven oversight, not foreign production itself.

“The FDA never inspects foreign factories.” It does, though historically with advance notice and backlogs; 2025 policy aims to increase unannounced inspections.

“Brand-name drugs are always made in the U.S.” Brand-name drugs are also made around the world, often using global ingredient suppliers.

Key Terms

Active pharmaceutical ingredient (API): The component of a medicine that produces its therapeutic effect.

Current good manufacturing practice (cGMP): FDA regulations for drug manufacturing quality.

Preannounced inspection: An inspection scheduled with advance notice to the facility.

WHO prequalification: WHO assessment allowing UN agencies to procure a medicine or vaccine.

Mutual recognition agreement: An arrangement allowing regulators to rely on each other’s inspections.

The Bottom Line

The claim that vaccines would be made in China and sold to Americans without inspection was misleading: U.S. vaccines require FDA licensure and facility inspections. But the underlying concern about oversight of foreign drug manufacturing is real. Much of America’s generic drug supply depends on factories in India and China, most foreign inspections have been preannounced, and quality failures have harmed patients. The FDA’s 2025 expansion of unannounced foreign inspections is a step toward closing the gap, though staffing and logistics remain challenges.

Vaccine Manufacturing and Supply

Vaccine production differs from most drug manufacturing in its complexity and concentration. Many vaccines are made by a few large companies at specialized plants, and producing a vaccine can take months, including growing biological materials, purifying them, formulating, filling vials, and extensive quality testing of each lot. FDA reviews lot release protocols for many vaccines before they are distributed. This concentrated, highly regulated system contributes to vaccine safety but can also make supply vulnerable to disruptions at individual plants, which has occasionally led to shortages of specific vaccines. Global initiatives have sought to expand vaccine manufacturing in Africa, Asia, and Latin America to improve regional supply, with WHO prequalification ensuring quality for vaccines purchased by international agencies.

Questions to Ask Your Pharmacist

Who manufactured my medicine, and has the manufacturer changed recently? Has this product been involved in any recalls? If the medicine is in shortage, what alternatives are available? Is there any reason to prefer a particular manufacturer’s version for my condition? How should I store this medicine to maintain its quality? Pharmacists are trained to answer these questions and can access recall and shortage information quickly.

International Cooperation

Drug quality is a global concern. Regulators from many countries cooperate through organizations such as the International Council for Harmonisation, which develops common technical standards for drug development and manufacturing, and the Pharmaceutical Inspection Co-operation Scheme, which promotes consistent inspection practices. The World Health Organization supports regulatory capacity in low- and middle-income countries and runs prequalification programs. Stronger regulators worldwide reduce risks for every country that depends on global supply chains, including the United States.

The Clinton Health Access Initiative’s Actual Role

The Clinton Health Access Initiative, along with foundations, UN agencies, and governments, has worked for years to lower the prices of medicines and vaccines for low- and middle-income countries, often by negotiating with manufacturers and supporting producers in emerging economies to meet international quality standards. These efforts have expanded access to HIV medicines, malaria treatments, and vaccines in countries that could not afford higher prices. Such work involves manufacturers in India, China, and elsewhere, but it is aimed at international procurement, not at supplying the U.S. market, which has its own regulatory requirements. The viral claim conflated this global health work with U.S. vaccine supply.

What Experts Recommend

Policy experts and government auditors have suggested several measures to strengthen oversight of foreign drug manufacturing: increasing unannounced inspections; hiring and retaining more investigators, including those who speak local languages; improving data on where active ingredients are made; requiring manufacturers to report quantities produced for the U.S. market; using remote record reviews and data analytics to target inspections; and expanding cooperation with trusted foreign regulators. Many of these recommendations appear in GAO reports and have been partially implemented, and the 2025 policy changes aim to accelerate progress.

Key Facts at a Glance

Vaccines sold in the U.S. require FDA licensure, including facility inspection, and are mostly made in the United States and Europe. Many generic drugs and active ingredients come from India and China, the two countries with the most foreign drug facilities subject to FDA inspection. Nearly 90 percent of FDA foreign inspections in fiscal 2023 were preannounced. FDA drug and device inspections in China rose from 8 in fiscal 2022 to 227 in fiscal 2024. In May 2025, an executive order and FDA announcement set out plans to expand unannounced foreign inspections, funded by higher fees. Past failures, including contaminated heparin in 2008 and contaminated artificial tears in 2023, illustrate the stakes.

Patients who have questions about where their medicines come from can start with their pharmacist, who has access to manufacturer, recall, and shortage information that is not always printed on the bottle.

Further Reading

For readers interested in this topic, the GAO has published a series of reports on FDA oversight of foreign drug manufacturing, available on its website. The FDA posts warning letters, import alerts, recalls, and drug shortage information publicly. Legal analyses from law firms and trade publications track policy changes such as the 2025 expansion of unannounced inspections. Academic research on drug shortages and supply chain resilience provides deeper context on why problems occur and what reforms might work. Reading across these sources gives a fuller picture than any single headline.

Patients, clinicians, and policymakers all share an interest in a medicine supply that is both affordable and reliably high in quality, and stronger oversight of the global supply chain is a central part of achieving that goal.

A Balanced View

The global pharmaceutical supply chain has made many medicines affordable and widely available, and the large majority of products reaching U.S. patients meet quality standards. At the same time, documented failures and longstanding oversight gaps justify the attention policymakers are now giving to foreign manufacturing. Accurate information helps avoid two errors: believing that all foreign-made medicines are dangerous, which could lead patients to stop needed treatment, and assuming that oversight is already sufficient, which could allow problems to persist. Supporting stronger inspections, transparency, and diversified supply is a reasonable middle path.

How Shortages Affect Patients

When quality problems shut down a key manufacturing site, patients may face delays, substitutions, or rationing. During the 2023 chemotherapy shortages, some cancer centers prioritized patients most likely to benefit, and others switched to alternative regimens. Shortages of antibiotics, ADHD medications, and other drugs have also caused difficulties in recent years for varied reasons, including manufacturing problems, demand surges, and economic factors. Patients affected by a shortage can work with their clinicians and pharmacists to identify safe alternatives and should not ration or stop medications without professional guidance. Understanding where medicines come from helps explain why these disruptions happen and why supply chain resilience has become a priority.

Hospitals and health systems increasingly monitor their supply chains, keep safety stocks of critical drugs, and work with multiple suppliers when possible to reduce the impact of disruptions on patients.

How Drug Quality Is Tested Before Release

Before a batch of medicine is released, manufacturers must test it against specifications for identity, strength, purity, and quality, and keep detailed records. For many products, U.S. distributors and some pharmacies also rely on certificates of analysis from manufacturers. The FDA conducts its own sampling and testing of marketed drugs, including imported products, and laboratories have developed methods to detect contaminants such as nitrosamines after past incidents. Data integrity, meaning that test results are accurate and records are not falsified, is critical; many FDA warning letters to foreign manufacturers have cited data integrity failures, which undermine confidence in all of a facility’s results.

Readers who encounter future headlines about medicines or vaccines made overseas can ask a few key questions: Is the product actually approved for sale in the United States? Has the FDA inspected the facility, and when? Are there documented quality problems or recalls? Answering these questions separates real concerns about oversight from misleading claims.

Ultimately, a safer medicine supply depends on cooperation among regulators, manufacturers, purchasers, and patients. Inspections catch problems, but sustainable quality also requires manufacturers to invest in robust systems and purchasers to value reliability, not just low prices. Patients contribute by reporting problems and staying informed about recalls and shortages that affect their care.

The Valsartan Recalls

In 2018, regulators recalled many generic versions of valsartan, a blood pressure drug, after finding a probable human carcinogen, NDMA, in active ingredient made by a manufacturer in China. The discovery led to wider testing and recalls of related drugs and to new FDA requirements for manufacturers to assess and control nitrosamine impurities.

Frequently Asked Questions

Are most U.S. medicines made in China?

Not exactly, though China plays a major role. The United States manufactures many finished drugs domestically and imports others from Europe and India. Its deepest dependence on China is for active pharmaceutical ingredients and the chemical precursors used to make them, particularly for generic medicines. So viral claims that nearly all U.S. drugs come from China overstate a more complex reality.

Where do America’s drugs and their ingredients come from?

Drug manufacturing is a global supply chain. Finished medicines are produced in the United States, Europe, India, and elsewhere, while many of the active ingredients and their chemical building blocks come from China and India. This means a medicine labeled as made in one country may still rely on ingredients produced on the other side of the world.

Does the FDA inspect foreign drug factories?

Yes. The FDA inspects both domestic and foreign facilities that make drugs for the U.S. market and can refuse imports from plants that fail inspection. However, foreign factories have historically been inspected less often than domestic ones, and the COVID-19 pandemic disrupted inspections, raising concerns about oversight of the increasingly global supply chain.

Why does drug manufacturing cause shortages?

When the production of a critical drug or ingredient is concentrated in just a few facilities, often overseas, a single disruption can ripple through the system. A factory shutdown, quality failure, natural disaster, or export restriction can cut off supply with few alternatives, leading to shortages. This concentration is a key vulnerability in the pharmaceutical supply chain.

Are generic drugs lower quality because of where they are made?

No, not as a rule. Approved generic drugs must meet the same FDA standards for quality, strength, purity, and effectiveness as brand-name drugs, regardless of where they are manufactured. Specific factories have had quality problems that led to recalls, but these are individual cases, not evidence that generics or foreign-made drugs are inferior overall.

References

1. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. New England Journal of Medicine. 2008;359(25):2674–2684. PMID 19052120
2. Grossman MK, Rankin DA, Maloney M, et al. Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases. 2024;79(1):6–14. PMID 38315890
3. Mondaq. FDA Foreign Inspections: Key Developments and Strategic Shifts. 2025. mondaq.com
4. FDA Law Blog. Knock Knock… Surprise, it’s FDA! May 2025. thefdalawblog.com
5. Global Compliance News. FDA to enhance unannounced inspections of foreign manufacturing facilities in countries including China. 2025. globalcompliancenews.com
6. McGuireWoods. FDA to Expand Unannounced Inspections of Foreign Facilities. May 2025. mcguirewoods.com
7. Pharma Manufacturing. 10 companies hit by FDA’s 2025 inspection crackdown. April 2025. pharmamanufacturing.com

Last updated: October 6, 2026